Generate Biomedicines (NASDAQ:GENB) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.57) by 8.77 percent. This is a 73.2 percent increase over losses of $(1.94) per share from the same period last year. The company reported quarterly sales of $6.314 million which missed the analyst consensus estimate of $6.625 million by 4.69 percent. This is a 37.67 percent decrease over sales of $10.130 million the same period last year.